We are live on ! Find out more
MACM

March Altus Capital Management Portfolio holdings

AUM $16M
1-Year Est. Return 18.92%
This Fund
S&P 500
This Quarter Est. Return
-8.76%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17M
AUM Growth
-$224K
Cap. Flow
+$2.44M
Cap. Flow %
14.36%
Top 10 Hldgs %
86.05%
Holding
28
New
8
Increased
3
Reduced
3
Closed
14

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$4.93M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.03M
3
GILD icon
Gilead Sciences
GILD
+$1.91M
4
PETX
Aratana Therapeutics, Inc.
PETX
+$1.87M
5
MDVN
MEDIVATION, INC.
MDVN
+$931K

Top Sells

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$2.08M
2
UTHR icon
United Therapeutics
UTHR
+$1.2M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$1.07M
4
THOR
THORATEC CORPORATION
THOR
+$1.05M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$983K

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
2 Miscellaneous 4.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYNO
26
DELISTED
Cynosure, Inc. Class A
CYNO
– –
-25,475
Closed -$983K
THOR
27
DELISTED
THORATEC CORPORATION
THOR
– –
-23,486
Closed -$1.05M
RCPT
28
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-2,251
Closed -$428K
1
2

Similar funds

IC
IKOS CIF Limassol, Cyprus $16.7M AUM 0.4% 1-Year Est. Return
PA
Para Advisors New York $17.5M AUM 3.99% 1-Year Est. Return
GMIM
General Motors Investment Management New York $20.3M AUM 55.51% 1-Year Est. Return
JHWCP
J.H. Whitney Capital Partners New Canaan, Connecticut $11.5M AUM 86.36% 1-Year Est. Return
SMPIAI
Spark Management Partners III (AIV I) Boston, Massachusetts $10.1M AUM 12.29% 1-Year Est. Return
NCMG
NCM Capital Management Group Durham, North Carolina $8.24M AUM 11.99% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return
GPI
Georgian Partners I Toronto, Ontario, Canada $25.3M AUM 21.88% 1-Year Est. Return

March Altus Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, March Altus Capital Management held 28 positions worth $17M, down 1.3% from $17.2M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

March Altus Capital Management deployed $2.44M of net new capital in Q3 2015, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Edwards Lifesciences: 204,414 shares worth $4.84M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was United Therapeutics, an estimated $1.2M trimmed.

  • March Altus Capital Management's largest Q3 2015 buy was Edwards Lifesciences: 204,414 shares worth $4.84M.
  • March Altus Capital Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2015, an estimated $455K increase.
  • March Altus Capital Management's biggest Q3 2015 reduction was United Therapeutics, cutting an estimated $1.2M.
  • March Altus Capital Management fully exited Universal Health Services in Q3 2015, selling an estimated $2.08M.
  • March Altus Capital Management's ten largest holdings make up 86% of its $17M portfolio in Q3 2015.
  • March Altus Capital Management opened 8 new positions and closed 14 in Q3 2015.
  • March Altus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $17M.

Based on March Altus Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.